Overview
Antal Rohit Desai, a director at PROCEPT BioRobotics Corp (NASDAQ:PRCT), executed multiple purchases of the company's common stock between March 5 and March 9, 2026, with the aggregate value of those purchases recorded at $10,482,942. The transactions took place while the stock was trading at $25.26, a level that represents a 57% decline over the past year. InvestingPro analysis included in the publicly available materials suggests the stock may be undervalued at current prices.
Transaction details
The purchases were made at prices that ranged from $23.3282 to $26.4073 per share. The specific trades reported are:
- March 5 - 142,498 shares and 24,748 shares;
- March 6 - 106,554 shares and 53,763 shares;
- March 9 - 43,581 shares, 53,818 shares and 1,300 shares.
Following these transactions, Desai's holdings are recorded as 35,152 shares held directly, 426,262 shares held indirectly through Kestrel Fund, L.P., and 14,363 shares held by The 2:22 DNA Trust.
Balance sheet note and research availability
InvestingPro Tips noted that the company carries more cash than debt on its balance sheet. For readers seeking broader context, a comprehensive Pro Research Report covering PRCT and more than 1,400 other U.S. equities is referenced in the same informational feed.
Recent operating and analyst developments
Procept BioRobotics reported fourth-quarter results that fell short of expectations, and the company subsequently lowered its 2026 guidance. In response, a number of sell-side analysts adjusted their models and targets:
- Piper Sandler reduced its price target to $28 from $50 and maintained an Overweight rating;
- Truist Securities cut its target to $30 from $47 while keeping a Buy rating, citing lower 2027 forecasts;
- TD Cowen reiterated a Buy rating and set a $34 price target, noting confidence in recent commercial changes despite the stock's sizable decline;
- Baird initiated coverage with a Neutral rating and a $30 price target.
Board change
The company also announced the appointment of Daniel Puckett to its board of directors and its audit committee. Mr. Puckett increases the board size from eight to nine members and will serve as a Class III director, with his term expiring at the 2027 annual meeting.
What this filing shows
The trades disclose a significant director purchase program involving both direct and indirect holdings, occurring against a backdrop of disappointing quarterly performance and downward revisions to near-term guidance. Analyst coverage now reflects a range of views on valuation and future performance, with some firms lowering targets but maintaining positive ratings, and at least one firm initiating a neutral stance.
Key points
- Insider buying: Director Antal Rohit Desai purchased company shares worth $10,482,942 across multiple trades from March 5-9, 2026.
- Company context: Procept reported a weaker fourth quarter and trimmed its 2026 guidance; the stock trades at $25.26, down 57% year-over-year.
- Analyst reaction: Several firms adjusted price targets and ratings, spanning reductions and reiterations of Buy/Overweight stances as well as a Neutral initiation.
Risks and uncertainties
- Operational risk - The company reported fourth-quarter results below expectations and lowered 2026 guidance, introducing uncertainty about near-term performance.
- Market sentiment risk - Significant analyst target reductions and mixed ratings could affect investor perception and share price volatility.
- Concentration risk - The filing shows substantial indirect holdings through specific entities, which could influence future liquidity or ownership dynamics.
Conclusion
The recent filings show a sizeable director purchase program concurrent with weaker reported results and a pullback in analyst price targets. The transactions increase Desai's direct and indirect exposure to PRCT while the company navigates lowered guidance and continued analyst reassessments. Investors seeking further detail may consult the referenced Pro Research Report and InvestingPro materials for additional data.